检索

A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian

Poddubnaya I., Kolyadina I., Kalashnikov N., Borisov D., Makarova M.

卷 26, 编号 4 (2024)

A clinical case of treatment of recurrent inoperable locally advanced breast cancer using conformal radiotherapy. Case report

Medvedev S., Vlasova M., Bolotina L., Kaprin A., Khmelevskiy E., Zikiryakhodzhaev A., Khakimova S., Khakimova G., Bychkova N., Zaitseva N., Abushova E., Guseva S., Maslov E.

(Rus)

Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review

Kolyadina I.

(Rus)

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (Russian Translation of Cochrane Plain Language Summary)

Uvarova K.

(Rus)

卷 26, 编号 3 (2024)

New therapies for hormone-positive HER2-negative metastatic breast cancer with AKT signaling alterations: the Expert Panel Decision

Editorial B.

(Rus)

Avastin in clinical chemotherapy of malignant tumors

Gorbunova V.

Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

Sokolova T., Solov'eva T., Aleksakhina S., Janus G., Goryainova A., Gluzman M., Orlova R., Stukan A., Zukov R., Zyuzyukina A., Murunova Y., Sultanbaev A., Vorobeva E., Mikhaevich L., Pyliv V., Lysenko A., Khachmamuk Z., Kozlov A., Bakharev S., Parsyan S., Rossokha E., Osidze L., Shumskaya I., Agaeva A., Kasmynina T., Klimenko V., Akhmetgareeva K., Vakhitova A., Chakhkieva M., Dmitriev V., Bakshun Y., Vasilyev A., Gasimly D., Kravchenko N., Maksimov D., Nesterova A., Sharvashidze I., Gadzaova C., Rakhmankulova G., Khamgokov Z., Amirkhanova I., Bembeeva L., Vladimirov V., Petrenko O., Ruskova N., Serikova E., Subbotina K., Tkachenko S., Chang V., Erdniev S., Barbara V., Vasilevskaya A., Mikheeva Y., Popova N., Startseva E., Fateeva A., Yukalchuk D., Grechkina A., Musaeva K., Odintsova S., Stel'makh A., Khabibulaeva P., Khlobystina A., Shvaiko K., Basova E., Bogomolova I., Bolieva M., Goldberg V., Kibisheva M., Menshikov K., Ryazanov D., Stepanova M., Udalova Y., Shkradyuk A., Chapko Y., Shchukina A., Khabriev I., Kirtbaya D., Degtyarev A., Epkhiev A., Tyugina Y., Murachuev M., Togo A., Ievleva A., Imyanitov E.

(Rus)

(Eng)

Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review

Sultanbaev A., Kolyadina I., Gilyazova I., Nasretdinov A., Musin S., Sultanbaeva N., Menshikov K.

(Rus)

卷 15, 编号 3 (2013)

Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii

Kolyadina I., Poddubnaya I., Trofimova O., Komov D., Karseladze A., Ermilova V., Vishnevskaya Y., Frank G., Banov S.

卷 27, 编号 1 (2025)

Long-term aesthetic outcomes of reconstructive surgeries with endoprosthetics for breast cancer: A review

Khomidi U., Vlasova M., Saribekyan E., Zikiryakhodzhaev A., Khakimova S., Khakimova G., Kodzoeva D.

(Rus)

Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)

Kolyadina I., Poddubnaya I., Van de Velde C., Kuppen P., Frank G., Komov D., Karseladze A., Bastiaannet E., Dekker-Ensink N.

Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review

Kolyadina I.

(Rus)

卷 23, 编号 3 (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer

Editorial B.

(Rus)

卷 15, 编号 2 (2013)

Prognostic value of p53 expression in patients with stage I breast cancer

Kolyadina I., Poddubnaya I., Van de Velde C., Kuppen P., Liefers G., Dekker-Ensink N., Bastiaannet E., Van As-Sajet A., Prinse B., Engels C., Van Vlierberghe R., Komov D., Karseladze A., Ermilova V., Vishnevskaya Y., Frank G., Banov S.

卷 18, 编号 2 (2016)

Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype

Karabina E., Zhukova L.

(Rus)

Influence of radiation therapy on the development of complications in single-stage autologous breast reconstruction with a DIEP-flap in breast cancer patients: a retrospective study

Duadze I., Kaprin A., Zikiryakhodzhaev A., Reshetov I., Usov F., Rasskazova E., Sukhotko A., Starkova M., Bagdasarova D., Dzhabrailova D., Khakimova S.

(Rus)

卷 22, 编号 1 (2020)

Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer

Kolyadina I., Danzanova T., Khokhlova S., Trofimova O., Kovaleva E., Rodionov V., Poddubnaya I.

(Rus)

卷 20, 编号 3 (2018)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer

Kolyadina I., Poddubnaya I.

(Rus)

The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan

Berdimyradova M., Khadjiev S., Khommadova D., Polatova G., Kakajanova A., Batyrov C., Penayev D., Agayeva B., Annaberdiyeva G.

(Rus)

卷 19, 编号 1 (2017)

Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer

Pavlikova O., Kolyadina I., Komov D., Vishnevskaya Y., Poddubnaya I.

(Rus)

卷 18, 编号 1 (2016)

Rare morphological forms of breast cancer: features of surgical approach

Vysotskaya I., Letyagin V., Kolyadina I., Martynova G.

(Rus)

卷 21, 编号 3 (2019)

The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer

Gordeeva O., Kolyadina I., Zhukova L., Gan'shina I., Komov D., Meshcheriakov A.

(Rus)

Squamous cell breast cancer: description of a rare clinical case

Zikiryakhodjaev A., Khakimova S., Rasskazova E., Saribekian E., Omarova D., Surkova V., Khakimova G.

(Rus)

卷 11, 编号 4 (2009)

Denosumab (AMG-162) v profilaktike osteoporoza, vyzvannogo priemom ingibitorov aromatazy u bol'nykh rakom molochnoy zhelezy v ad\"yuvantnoy terapii i u bol'nykh rakom predstatel'noy zhelezy pri polnoy androgennoy blokade

Lichinitser M., Semenov N.

Experience in the treatment of radioinduced angiosarcoma of the breast in a patient with primary multiple lesions of the breast and bladder. Case report

Semenov E., Gasymly D., Zyuzyukina A., Zukov R.

(Rus)

The use of combined plastic interventions in the reconstruction of post-operative soft tissue defects of the chest wall in the surgical treatment of locally advanced breast cancer

Vashenko L., Daschkova I., Bakulina S., Andreyko E.

卷 24, 编号 2 (2022)

Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study

Sultanbaev A., Menshikov K., Musin S., Nasretdinov A., Fatikhova A., Izmailov A., Lipatov O., Ayupov R., Sultanbaeva N., Menshikova I., Serebrennikov G.

(Rus)

Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study

Golubenko E., Savelyeva M., Poddubnaya I., Korennaya V.

(Rus)

卷 19, 编号 2 (2017)

PARP inhibitors in female reproductive system cancers

Pokataev I., Tyulyandin S.

(Rus)

Benefits and limitations of breastfeeding for mothers with malignant tumors

Ladodo O., Iurova M., Khokhlova S., Rodionov V., Sheshko E., Zubkov V., Makieva M., Chutkova D., Akhapkina E., Degtyarev D.

(Rus)

Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study

Evdokimov V., Bloshchinenko A., Abolmasov A., Vilensky A., Laskov M.

(Rus)

卷 21, 编号 1 (2019)

The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review)

Morozov D., Kolyadina I., Poddubnaya I., Chumakov P., Ilinskaya G., Bokhian V., Sopova M.

(Rus)

Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study

Zabotina T., Chertkova A., Borunova A., Kushlinskii N., Gershtein E., Zakharova E., Shoua E., Tsiklauri V., Samoylenko I., Khoroshilov M., Kadagidze Z.

(Rus)

卷 8, 编号 1 (2006)

Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy

卷 26, 编号 2 (2024)

Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review

Grechukhina K., Filonenko D., Sukhova M., Zhukova L.

(Rus)

卷 25, 编号 2 (2023)

Breast cancer: genetic personal risk factors: A review

Zolotykh M., Bilyalov A., Nesterova A., Gimranov A., Filina J., Rizvanov A., Miftakhova R.

(Rus)

卷 24, 编号 2 (2022)

Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes

Snegovoy A., Kononenko I.

(Rus)

Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021

Board E.

(Rus)

Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer

Nenahova Y., Lyadov V., Poddubnaya I.

(Rus)

The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015

Poddubnaya I., Frank G., Yagudina R., Koroleva N., Zavalishina L.

(Rus)

卷 17, 编号 2 (2015)

Stereotactic biopsy of breast lesions under x-ray control

Manikhas G., Safronova O., Khudjakova T., Barabanova L., Punanova N.

Personalized approach to HER2-positive advanced breast cancertherapy

Stenina M.

卷 15, 编号 4 (2013)

Bone mineral density in patient with breast cancer

Poddubnaya I., Kizhaev E., Kolyadina I., Banov S., Zhmaeva E., Secko M.

卷 11, 编号 3 (2009)

Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy

Semiglazov V., Semiglazov V., Zhil'tsova E.

Kachestvo zhizni i simptomyu bol'nykh disseminirovannym gormonopozitivnym rakom molochnoy zhelezy v postmenopauze na fone primeneniya Fazlodeksa

Novik A., Ionova T., Kalyadina S.

Femara (letrozol) v ad\"yuvantnoy terapii raka molochnoy zhelezy

Stenina M.

卷 8, 编号 4 (2006)

Vliyanie rekonstruktivno-plasticheskikh operatsiy na kachestvo zhizni bol'nykh rakom molochnoy zhelezy v otdalennom periode

Arslanov K., Tkachenko G.

卷 8, 编号 1 (2006)

Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy

Samoylenko V., Gorbunova V., Koshelev M., Yurashko K.

卷 7, 编号 1 (2005)

Faktory prognoza pri rake molochnoy zhelezy

Bozhok A., Semiglazov V., Semiglazov V., Arzumanov A., Kletsel' A.

Mammography followed by ultrasonography compared to mammography alone for breast cancer screening in women at average risk of breast cancer (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)

Editorial B.

(Rus)

PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021

Use of psychological interventions in women diagnosed and under treatment for non-metastatic breast cancer [Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review]

Mustafina F.

(Rus)

卷 23, 编号 4 (2021)

Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III

Morozov D., Kolyadina I., Poddubnaya I., Ganshina I., Khokhlova S., Kоmetova V., Rodionov V.

(Rus)

卷 23, 编号 2 (2021)

Board E.

(Rus)

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform

Board E.

(Rus)

Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor

Ganshina I., Ivanova K., Lubennikova E., Arkhipov A., Zhukova L.

(Rus)

卷 22, 编号 2 (2020)

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

Kolyadina I., Ganshina I., Kuzmicheva S., Tekeeva A., Kolokolov J., Volkonskii M., Poddubnaya I.

(Rus)

(Eng)

卷 21, 编号 3 (2019)

Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population

Grechukhina K., Zhukova L.

(Rus)

卷 21, 编号 1 (2019)

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia

Gorbunova V., Kolyadina I., Kovalenko E., Manziuk L., Artamonova E., Zhukova L., Bolotina L., Semiglazova T., Manikhas A., Raevskaia N., Itkin I., Filonenko D., Zhilyaeva L., Gol'dberg V., Popova N., Ponomarenko D., Shikina V., Suslova I., Romanchuk O., Kozlov D., Rzaev A., Marfutov V., Andreiashkina I., Vladimirova L., Mitashok I., Tikhanovskaia N., Karabina E., Mukhametshina G., Khasanova A., Safina S., Shaidorov M., Morozov D., Prokof'eva E., Kramskaia L., Karandeeva T., Evstigneeva I., Ovchinnikova E., Klement'eva T., Khrupalo O., Tiuvinova E., Sherstnev V., Chernov I., Kolokolov D., Gaisina E., Levchenko N., Chubenko V., Povyshev A., Iudina I., Vorotilina L., Andreeva T., Tumanian G., Koziakov A., Gil'mutdinova L., Osipov M., Shatokhina A., Vazhenina A., Chichkanova A., Vladimirov V., Ivanov A., Belokhvostova A., Cherniakova E., Tul'china E., Maklashova S., Shkodenko O., Kostalanova I., Tarasova A., Kuz'mina E.

(Rus)

卷 19, 编号 4 (2017)

Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0

Pavlikova O., Poddubnaya I., Kolyadina I., Abdullaev A., Komov D., Danzanova T., Sinyukova G., Kozlov N., Ganshina I., Zhukova L., Aliyeva G., Kerimov R., Gordeeva O.

(Rus)

卷 19, 编号 1 (2017)

Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin

Kolbin A., Mosikyan A., Kurilev A., Balykina Y., Proskurin M.

(Rus)

卷 18, 编号 4 (2016)

Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer

Vladimirova L.

卷 17, 编号 2 (2015)

Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy

Artamonova E., Manziuk L.

High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)

Seryakov A., Ovchinnikova L., Zabelin M., Yakubov T., Sidorov D., Ovchinnikov M.

卷 15, 编号 2 (2013)

New possibilities of chemotherapy for anthracyclineand/or taxane-resistant breast cancer

Artamonova E., Manzyuk L.

卷 11, 编号 4 (2009)

Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy

Artamonova E.

HER-2-targetnaya terapiya raka molochnoy zhelezy: monoklonal'nye antitela i ingibitory tirozinkinazy

Ognerubova I.

Regional'naya programma lecheniya bol'nykh pervichno-generalizovannym i metastaticheskim rakom molochnoy zhelezy

卷 9, 编号 2 (2007)

Ad\"yuvantnaya endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy

Semiglazov V., Semiglazov V.

卷 7, 编号 2 (2005)

Biologicheskie kharakteristiki opukholi (proliferativnaya aktivnost', ploidnost' i steroidnye retseptory) i ikh vliyanie na neposredstvennye i otdalennye rezul'taty lecheniya zapushchennogo raka molochnoy zhelezy

Nikolaeva T., Vyshinskaya G., Rotobel'skaya L.

卷 26, 编号 3 (2024)

Predictive modeling of the probability of gynecological complications of tamoxifen therapy: A prospective study

Golubenko E., Savelyeva M., Korennaya V., Podzolkova N., Valiev T.

(Rus)

Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research

Kolomejtseva A., Bokova S.

(Rus)

卷 23, 编号 4 (2021)

The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

Shlivko I., Garanina O., Artamonova E., Ganshina I., Zhukova L., Koroleva I., Michenko A., Semiglazova T., Filonenko D.

(Rus)

卷 23, 编号 2 (2021)

Synchronous thyroid gland metastases from breast cancer. Case reports

Ognerubov N., Antipova T., Palkina E.

(Rus)

Breast cancer

Zhukova L., Andreeva I., Zavalishina L., Zakiriakhodzhaev A., Koroleva I., Nazarenko A., Paltuev R., Parokonnaia A., Petrovskii A., Portnoi S., Semiglazov V., Semiglazova T., Stenina M., Stepanova A., Trofimova O., Tyulyandin S., Frank G., Frolova M., Shatova I., Nevol’skikh A., Ivanov S., Khailova Z., Gevorkian T.

(Rus)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer

Ganshina I., Gordeeva O., Manukian M.

(Rus)

卷 22, 编号 1 (2020)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

Kovalenko E., Artamonova E., Karabina E., Andreiashkina I., Prokof’eva E., Popova N., Gaisina E., Evstigneeva I., Shaidorov M., Zhiliaeva L., Ponomarenko D., Khasanova A., Mukhametshina G., Koziakov A., Vorotilina L., Povyshev A., Simolina E., Marfutov V., Kozlov D., Suslova I., Shikina V., Karandeeva T., Shepel’ A., Kramskaia L., Oskirko D., Frolova O.

(Rus)

卷 21, 编号 2 (2019)

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience

Kolyadina I., Bulavina I., Petkau V., Strakhova N., Gorbunova V., Kovalenko E., Manziuk L., Artamonova E., Zhukova L., Bolotina L., Gan'shina I., Semiglazova T., Manikhas A., Raevskaia N., Itkin I., Khokhlova S., Filonenko D., Gol'dberg V., Popova N., Ponomarenko D., Shikina V., Vladimirova L., Tikhanovskaia N., Karabina E., Mukhametshina G., Khasanova A., Safina S., Shaidorov M., Orlov A., Kostalanova I., Levchenko N., Osipov M., Karandeeva T., Evstigneeva I., Chernov I., Kolokolov D., Povyshev A., Shatokhina A., Cherniakova E., Shkodenko O., Kuz'mina E.

(Rus)

The post-mastectomy syndrome: the secondary lympedema after the combined treatment of breast cancer (the literature review and own results)

Stepanova A., Merzlyakova A., Khulamhanova M., Trofimova O.

(Rus)

卷 20, 编号 1 (2018)

Dermatomyositis and polymyositis in breast cancer patients: a case reports

Ganshina I., Zhukova L., Burnevitch E., Gordeeva O., Kondratieva O.

(Rus)

卷 19, 编号 2 (2017)

Perspectives of pharmacogenetics approach to personalized tamoxifen therapy

Savelyeva M., Ignatova A., Panchenko Y., Urvantseva I., Poddubnaya I.

(Rus)

卷 18, 编号 2 (2016)

New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer

Semiglazova T., Klyuge V., Semiglazov V., Teletaeva G., Krivorotko P., Dashyan G., Paltuev R., Tkachenko E., Donskikh R., Semiglazov V.

(Rus)

卷 17, 编号 3 (2015)

The results of Epidemiological HER2 screening program in patients with breast cancer in 2014

Poddubnaya I., Frank G., Yagudina R., Koroleva N., Zavalishina L.

卷 17, 编号 2 (2015)

The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients

Frank G., Ilatovskaia M., Andreeva I., Zavalishina L.

Press-reliz Na XIII Rossiyskom kongresse onkologov obsudili sostoyanie epidemiologicheskoy programmy skrininga HER2-statusa u zhenshchin, bol'nykh rakom molochnoy zhelezy (RMZh), a takzhe preimushchestvai perspektivy targetnoy terapii preparatami Gertseptin i Avastin

Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women

Jackisch C., Llombart-Cussac A.

卷 11, 编号 4 (2009)

Rol' Taksotera v lechenii metastaticheskogo raka molochnoy zhelezy

Kolyadina I., Makarenko N., Poddubnaya I.

Fulvestrant v sovremennoy terapii rasprostranennogo raka molochnoy zhelezy: farmakoekonomicheskoe obosnovanie

Komarova V., Komarova L., Poddubnaya I.

卷 9, 编号 2 (2007)

Sovremennaya taktika ad\"yuvantnoy lekarstvennoy terapii bol'nykh operabel'nym (rannim) rakom molochnoy zhelezy

Perevodchikova N.

卷 27, 编号 1 (2025)

Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review

Grechukhina K., Sukhova M., Kolyago E., Filonenko D., Zhukova L.

(Rus)

Isolated metastasis to the scalp in occult breast cancer: a clinical case

Ognerubov N., Sergeev R., Hizhnyak A., Ognerubova M., Dzhabrailov M.

(Rus)

Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report

Grechukhina K., Vorontsova K., Filonenko D., Tyutyunnik P., Shchadrova V., Zhukova L.

(Rus)

卷 23, 编号 3 (2021)

Can any breast skin thickening be staged as T4?

Amosova V., Petrovskii A., Karpova M., Ponedel’nikova N., Frolova M.

(Rus)

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

Mazurina N., Artamonova E., Beloyartseva M., Volkova E., Ganshina I., Troshina E., Tjulandin S., Chubenko V.

(Rus)

Opportunities for metastatic triple negative breast cancer therapy

Ganshina I., Gordeeva O., Manukyan M.

(Rus)

卷 19, 编号 2 (2017)

Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary?

Trigolosov A., Uimanov V., Chernikh M., Petrovskiy A., Nikitina E., Nechushkin M.

(Rus)

Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer

Semiglazova T., Dashyan G., Semiglazov V., Zhabina A., Osipov M., Kotova Z., Klimenko V., Krivorotko P., Semiglazov V.

卷 16, 编号 4 (2014)

Male breast cancer: review of the literature

Nikolaev K., Semiglazov V., Semiglazov V.

The results of Epidemiological HER2 screening program in patients with breast cancer in 2013

Frank G., Poddubnaya I., Yagudina R., Borisov D., Koroleva N.

Sravnitel'noe issledovanie opredeleniya HER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii

Zavalishina L., Andreeva Y., Ryazantseva A., Bateva M., Frank G.

Postmastektomicheskaya limfedema verkhnikh konechnostey: vozmozhnosti konservativnogo lecheniya

Myasnikova M.

卷 26, 编号 4 (2024)

Prognostic significance of androgen receptor expression in triple-negative breast cancer

Panchenko I., Panchenko S., Sharafutdinov M., Rodionov V., Kometova V., Burmenskaya O.

(Rus)

卷 25, 编号 4 (2023)

Scalp hypothermia for the prevention of chemotherapy-induced alopecia in breast cancer

Ognerubov N., Barsukov S.

(Rus)

The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review

Grechukhina K., Kalugin M., Prosvirnov A., Sukhova M., Zhukova L.

(Rus)

Antiangiogenic therapy for breast cancer with triple negative phenotype

Ganshina I., Ivanova K., Gordeeva O., Arkhipov A., Zhukova L.

(Rus)

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review

Poddubnaya I., Gligorov J., Zhukova L., Kovalenko E., Frolova M.

(Rus)

Ribociclib in 1st line HR+ breast cancer treatment

Zhukova L., Ganshina I., Gordeeva O., Lubennikova E.

(Rus)

卷 18, 编号 2 (2016)

Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast

Rudakova A., Tolkacheva D., Gavrilova O., Vaganov A.

(Rus)

卷 16, 编号 4 (2014)

Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)

Kolyadina I., Poddubnaya I.

Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board

Artamonova E., Gorbunova V., Zhukov N., Manzjuk L., Manihas A., Paltuev P., Semiglazov V., Semiglazova T., Stenina M., Tjuljandin S., Chubenko V.

卷 10, 编号 1 (2008)

Effektivnost' ad\"yuvantnoy terapii anastrozolom i tamoksifenom u patsientok s rannimi stadiyami raka molochnoy zhelezy (analiz dannykh issledovaniya ATAC pri mediane vremeni nablyudeniya 100 mes)

卷 9, 编号 2 (2007)

Sravnitel'noe issledovanie opredeleniya NER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii

Zavalishina L., Andreeva Y., Ryazantseva A., Bateva M., Frank G.

卷 7, 编号 3 (2005)

Sovremennye vozmozhnosti lekarstvennoy terapii operabel'nogo raka molochnoy zhelezy (po materialam St. Gallen, 2005)

Letyagin V., Vysotskaya I.

卷 7, 编号 2 (2005)

«Problema optimizatsii ad\"yuvantnoy endokrinnoy terapii na rannikh stadiyakh raka molochnoy zhelezy»

Semiglazov V., Poddubnaya I.

Classification of breast cancer subtypes based on RNA profiling and immunohistochemical methods: clinical and biological aspects: A review

Imyanitov E.

(Rus)

Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence

Editorial B.

(Rus)

卷 23, 编号 4 (2021)

Innovations in practice. 5 years of palbociclib experience in the Russian Federation. Overview of web-conference took place on 8 October 2021

Editorial B.

(Rus)

Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer

Samaneva N., Vladimirova L., Kolyadina I., Frantsiyants E., Storozhakova A., Bandovkina V., Kalabanova E., Kabanov S., Svetitskaya I., Tishina A., Ezhova M.

(Rus)

Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Frolova M., Kochetkova Y., Chubenko V., Volkov N., Moiseenko F., Garmarnik T., Ponomarenko D., Orlov A., Kostalanova Y., Makarycheva Y., Nizegorodzeva A.

(Rus)

卷 19, 编号 3 (2017)

Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer

Nenakhova Y., Lyadov V., Poddubnaya I.

(Rus)

卷 19, 编号 3 (2017)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving

Artamonova E.

(Rus)

卷 19, 编号 1 (2017)

Albumin-bound paclitaxel in the treatment of metastatic breast cancer

Artamonova E.

(Rus)

The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer

Frolova M.

(Rus)

卷 17, 编号 4 (2015)

Neoadjuvant systemic therapy of HER2-positive breast cancer

Frolova M.

Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial

Ahmetzanov F., Ahmetzanova F.

卷 16, 编号 1 (2014)

New chemotherapy options for triple-negative breast cancer (review of literature)

Sekundova M., Zdvizhkov A., Borisov V.

卷 11, 编号 1 (2009)

Problemy endokrinoterapii raka molochnoy zhelezy u muzhchin

Borisova E., Voronina I., Gutorov S.

Odnomomentnye mastektomii i laparoskopicheskie ovariektomii v lechenii raka molochnoy zhelezy

Khvastunov R., Kireev A., Nikol'skiy I., Suvorov V.

卷 7, 编号 1 (2005)

Opyt primeneniya Regional'noy programmy v g. Krasnodare

Mitashok I.

卷 26, 编号 4 (2024)

Immunological predictors of the therapeutic efficacy of atezolizumab in combination with nab-paclitaxel in metastatic triple-negative breast cancer: A pilot multicenter retrospective associative study

Kalinchuk A., Popova N., Gofman A., Usoltseva I., Perelmuter V., Tashireva L.

(Rus)

Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study

Sultanbaev A., Kolyadina I., Menshikov K., Musin S., Nasretdinov A., Sultanbaeva N., Rakhimov R., Lipatov D., Menshikova I., Izmailov A., Lipatova E.

(Rus)

Relationship of the integrin profile of the primary tumor to metastasis to regional lymph nodes in breast cancer

Zavyalova M., Kuznecov G., Grigoryeva E., Tashireva L., Pismenny D., Perelmuter V.

(Rus)

卷 25, 编号 2 (2023)

Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study

Chulkova S., Sholokhova E., Poddubnaya I., Stilidi I., Burov D., Tupitsyn N.

(Rus)

Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy: a regional analysis

Valiachmetova C., Siraev E., Izmailov A.

(Rus)

The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study

Chulkova S., Sholokhova E., Poddubnaya I., Stilidi I., Tupitsyn N.

(Rus)

The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia

Sokolova T., Aleksakhina S., Yanus G., Sultanbaev A., Menshikov K., Lysenko A., Zukov R., Zyuzyukina A., Murunova Y., Rossokha E., Bakharev S., Basova E., Kasmynina T., Shumskaya I., Bakshun Y., Musaeva K., Khasanova A., Dmitriev V., Bolieva M., Gadzaova C., Petrenko O., Maksimov D., Vladimirov V., Goldberg V., Popova N., Kibisheva M., Khamgokov Z., Vasilyev A., Iyevleva A., Imyanitov E.

(Rus)

卷 23, 编号 3 (2021)

The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer

Tabakov D., Zabotina T., Chanturia N., Zakharova E., Vorotnikov I., Selchuk V., Sokolovskiy V., Petrovsky A.

(Rus)

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Zhukova L., Ganshina I., Khatkova E., Tikhomirova T., Kondratyeva O.

(Rus)

卷 19, 编号 4 (2017)

Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case

Kolyadina I., Ganshina I., Zhukova L., Abdullaev A., Andreeva Y., Danzanova T., Sinyukova G., Komov D., Kozlov N., Filonenko D., Gordeeva O., Lubennikova E.

(Rus)

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia

Bolotina L., Manziuk L., Gorbunova V., Kovalenko E., Mukhametshina G., Khasanova A., Vladimirova L., Mitashok I., Prokofyeva E., Evstigneeva I., Andreyashkina I., Abramova N., Popova I., Karabina E., Teterich A., Gaysina E., Chubenko V., Limareva S., Tikhanovskaya N., Storozhakova A., Samaneva N., Svetitskaya Y., Snezhko T., Kalabanova E.

(Rus)

Radiation-induced lung injury in breast cancer patients after breast conservation therapy

Trofimova O., Tkachev S., Ivanov S., Utkina V., Cheban O., Glebovskaya V.

卷 16, 编号 4 (2014)

Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?

Kolyadina I., Poddubnaya I., Trofimova O., Frank G., Karseladze A., Komov D.